Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences (Nasdaq: SLDB) has granted 9,741 restricted stock units (RSUs) to a new employee as part of their inducement compensation package. The RSUs will vest in four equal annual installments, with full vesting occurring on the fourth anniversary of the grant date. The grant was issued under the Company's 2024 Inducement Stock Incentive Plan and complies with Nasdaq Listing Rule 5635(c)(4). Vesting is contingent upon the employee's continued employment with the company through each vesting date.
Solid Biosciences (Nasdaq: SLDB) ha concesso 9.741 unit脿 azionarie limitate (RSU) a un nuovo dipendente come parte del pacchetto di compenso per l'assunzione. Le RSU matureranno in quattro rate annuali uguali, con la completa maturazione che avverr脿 al quarto anniversario della data di concessione. La concessione 猫 stata emessa nell'ambito del 2024 Inducement Stock Incentive Plan della Societ脿 e rispetta la Regola di quotazione 5635(c)(4) del Nasdaq. La maturazione 猫 subordinata alla continuazione dell'impiego del dipendente presso l'azienda fino a ciascuna data di maturazione.
Solid Biosciences (Nasdaq: SLDB) ha otorgado 9,741 unidades de acciones restringidas (RSUs) a un nuevo empleado como parte de su paquete de compensaci贸n por inducci贸n. Las RSUs se consolidar谩n en cuatro cuotas anuales iguales, con la plena consolidaci贸n ocurriendo en el cuarto aniversario de la fecha de concesi贸n. La concesi贸n se realiz贸 bajo el 2024 Inducement Stock Incentive Plan de la Compa帽铆a y cumple con la Regla de Cotizaci贸n 5635(c)(4) de Nasdaq. La consolidaci贸n depende de que el empleado contin煤e trabajando en la compa帽铆a hasta cada fecha de consolidaci贸n.
Solid Biosciences (Nasdaq: SLDB)電� 靸堧鞖� 歆侅洂鞐愱矊 9,741臧滌潣 鞝滍暅 欤检嫕 雼渼 (RSU)毳� 鞙犽弰 氤挫儊 韺偆歆�鞚� 鞚柬櫂鞙茧 攵�鞐枅鞀惦媹雼�. RSU電� 雱� 彀鞚� 霃欕摫頃� 鞐瓣皠 頃犽秬搿� 攵勴暊霅橃柎, 攵�鞐澕搿滊秬韯� 4欤茧厔 霅橂姅 雮犾棎 鞝勲秬 鞕勳爠頌� 攴�靻嶋惄雼堧嫟. 鞚� 攵�鞐姅 須岇偓鞚� 2024 鞙犽弰 欤检嫕 鞚胳劶韹半笇 瓿勴殟鞐� 霐半澕 鞚措（鞏挫鞙茧┌, Nasdaq 靸侅灔 攴滌箼 5635(c)(4)毳� 欷�靾橅暕雼堧嫟. 攴�靻嶌潃 臧� 攴�靻嶌澕毵堧嫟 歆侅洂鞚� 須岇偓鞐� 歆�靻嶌爜鞙茧 鞛頃橂姅 臁瓣贝鞐� 霐半雼堧嫟.
Solid Biosciences (Nasdaq: SLDB) a accord茅 9.741 unit茅s d'actions restreintes (RSU) 脿 un nouvel employ茅 dans le cadre de son package de compensation d'incitation. Les RSU seront acquises en quatre versements annuels 茅gaux, avec une acquisition compl猫te se produisant au quatri猫me anniversaire de la date d'attribution. L'attribution a 茅t茅 effectu茅e dans le cadre du 2024 Inducement Stock Incentive Plan de la soci茅t茅 et respecte la r猫gle de cotation 5635(c)(4) de Nasdaq. L'acquisition est conditionn茅e 脿 la poursuite de l'emploi de l'employ茅 au sein de l'entreprise jusqu'脿 chaque date d'acquisition.
Solid Biosciences (Nasdaq: SLDB) hat 9.741 beschr盲nkte Aktieneinheiten (RSUs) an einen neuen Mitarbeiter als Teil seines Anreizverg眉tungspakets gew盲hrt. Die RSUs werden in vier gleichen j盲hrlichen Raten f盲llig, wobei die vollst盲ndige F盲lligkeit am vierten Jahrestag des Gew盲hrungsdatums erfolgt. Die Gew盲hrung wurde im Rahmen des 2024 Inducement Stock Incentive Plans des Unternehmens ausgegeben und erf眉llt die Nasdaq-B枚rsenzulassungsregel 5635(c)(4). Die F盲lligkeit ist abh盲ngig von der fortdauernden Besch盲ftigung des Mitarbeiters im Unternehmen bis zu jedem F盲lligkeitsdatum.
- None.
- None.
CHARLESTOWN, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc.聽(Nasdaq: SLDB) (the 鈥淐ompany鈥�), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 9,741 restricted stock units (鈥淩SUs鈥�) to one newly hired employee.
The RSUs vest in four equal installments on each one-year anniversary of the grant date until the fourth anniversary of the grant date. Vesting of the equity awards is subject to the employee鈥檚 continued service with the Company through each applicable vesting date.
This grant was made pursuant to the Company鈥檚 2024 Inducement Stock Incentive Plan and was made as an inducement material to the employee鈥檚 acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
About聽Solid Biosciences
Solid Biosciences is a life sciences company focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne), SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. Solid is advancing its diverse pipeline across rare neuromuscular and cardiac diseases, bringing together experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted, Solid鈥檚 mandate is to improve the daily lives of patients living with these devastating diseases. For more information, please visit .
Solid Biosciences Investor Contact:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
Media Contact:
Glenn Silver
FINN Partners
FAQ
How many RSUs did Solid Biosciences (SLDB) grant in November 2024?
What is the vesting schedule for Solid Biosciences' (SLDB) November 2024 RSU grant?
Under which plan were the November 2024 SLDB RSUs granted?
